Novartis deals with Ionis Pharmaceuticals Inc and Akcea Therapeutics Inc to license two experimental cardiovascular treatments

News Hour:

Novartis has agreed with Ionis Pharmaceuticals Inc and its affiliate Akcea Therapeutics Inc to license two experimental cardiovascular treatments in a deal which Ionis said could eventually be worth more than $1 billion.

The treatments aim to reduce cardiovascular risk in patients with high levels of lipoprotein. The therapies called AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx have the potential to lower lipoprotein Lip(a) and ApoCIII by up to 90 percent, Novartis said in a statement on Friday, reports Reuters.

Ionis and Akcea are eligible to receive $225 million in near-term payments, including a $75 million up-front option payment and a $100 million equity investment in Ionis, Ionis said in a separate statement.

Novartis joins forces with Ionis on cardiovascular treatments

 

The deal would be valued at “significantly over $1 billion” through license fees, milestone payments and royalties if both drugs are licensed and successfully commercialized, Ionis said.

Basel-based Novartis said it can exercise its options to license and commercialize the two products after they hit specified development milestones and before phase 3 trials for each program begin.

Novartis would then be responsible for worldwide development and commercialization of both assets. Shares in Novartis fell 14.6 percent in 2016, a steeper drop than the broader European healthcare index.

Avatar

This article has been posted by a News Hour Correspondent. For queries, please contact through [email protected]
No Comments

Translate this News

Join the Facebook Group

Click here to join the Facebook group of News Hour

Popular Posts

Advertisement

News of the Month

January 2017
S M T W T F S
« Dec   Feb »
1234567
891011121314
15161718192021
22232425262728
293031  
Scroll Up
%d bloggers like this: